FDA approves costly version of drug for rare disease

The FDA approved Raptor Pharmaceutical's Procysbi to treat nephropathic cystinosis, a rare, inherited pediatric disease. The drug was developed with financing from a foundation started by a patient's parents and is a more easily tolerated version of an existing drug, but Raptor set the price at $250,000.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ